Thermal Stability of Rhodopsin and Progression of Retinitis Pigmentosa

COMPARISON OF S186W AND D190N RHODOPSIN MUTANTS

Received for publication, July 2, 2012, and in revised form, April 24, 2013 Published, JBC Papers in Press, April 26, 2013, DOI 10.1074/jbc.M112.397257

Monica Yun Liu‡1,2**, Jian Liu**§3**, Devi Mehrotra**‡1**, Yuting Liu**§ **, Ying Guo**§ **, Pedro A. Baldera-Aguayo**§4**, Victoria L. Mooney**§5**, Adel M. Nour**¶ **, and Elsa C. Y. Yan**§6

From the Departments of ‡ *Molecular, Cellular, and Developmental Biology,* § *Chemistry, and* ¶ *Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut 06520*

Background: The S186W mutation in rhodopsin causes retinitis pigmentosa (RP).

Results: The mutation expedites thermal isomerization and hydrolysis of the Schiff base by orders of magnitude.

Conclusion: Lower thermal stability could link to higher levels of dark noise, associated with RP's early symptom, night blindness.

Significance: Further quantitative kinetic studies could potentially establish a correlation between thermal stability and RP progression.

Over 100 point mutations in the rhodopsin gene have been associated with retinitis pigmentosa (RP), a family of inherited visual disorders. Among these, we focused on characterizing the S186W mutation. We compared the thermal properties of the S186W mutant with another RP-causing mutant, D190N, and with WT rhodopsin. To assess thermal stability, we measured the rate of two thermal reactions contributing to the thermal decay of rhodopsin as follows: thermal isomerization of 11-*cis***-retinal and hydrolysis of the protonated Schiff baselinkage between the 11-***cis***retinal chromophore and opsin protein. We used UV-visible spectroscopy and HPLC to examine the kinetics of these reactions at 37 and 55 °C for WT and mutant rhodopsin purified from HEK293 cells. Compared with WT rhodopsin and the D190N mutant, the S186W mutation dramatically increases the rates of both thermal isomerization and dark state hydrolysis of the Schiff base by 1–2 orders of magnitude. The results suggest that the S186W mutant thermally destabilizes rhodopsin by disrupting a hydrogen bond network at the receptor's active site. The decrease in the thermal stability of dark state rhodopsin is likely to be associated with higher levels of dark noise that undermine the sensitivity of rhodopsin, potentially accounting for night blindness in the early stages of RP. Further studies of the thermal stability of additional pathogenic rhodopsin mutations in conjunction with clinical studies are expected to provide insight into the molecular mechanism of RP and test the correlation between rhodopsin's thermal stability and RP progression in patients.**

orders characterized by progressive degeneration of the retina and retinal pigment epithelium $(1-6)$. About 25% of autosomal dominant RP cases are connected to one of over 100 point mutations in the rhodopsin gene (7). Understanding the molecular mechanism of the individual genetic defects that cause RP is key to developing new treatments. Mechanisms such as misfolding and mistrafficking of mutant rhodopsin have been proposed to explain the cause of RP by different mutations, but the mechanisms for about half of the mutations remain unknown (8–10). Among these, the S186W mutation was identified clinically by Ruther *et al.* (11), but it has remained almost unexplored at the molecular level.

Retinitis pigmentosa $(RP)^7$ is a family of inherited visual dis-

Rhodopsin is a widely studied seven-helical transmembrane G protein-coupled receptor (12–21). Found in the peripheral retina, rhodopsin enables dim-light vision and accounts for over 90% of the protein in the disc membranes of the outer segment of rod cells (15, 22). Rhodopsin consists of the opsin apoprotein covalently bound to a chromophore, 11-*cis*-retinal, via a protonated Schiff base (SB) linkage at the Lys-296 residue (23). Upon absorption of a photon, 11-*cis*-retinal isomerizes to all-*trans*-retinal, initiating a series of conformational changes in the protein, resulting in the active form, metarhodopsin II (Meta II), which consists of all-*trans*-retinal bound to opsin by a deprotonated SB (21, 24–29). Meta II then activates the G protein transducin to trigger the visual signaling pathway, leading to the perception of light (30, 31).

In the early stages of RP, patients lose night vision and, in up to 35% of cases, see false flashes of light, a symptom known as photopsia (6, 32), suggesting that RP may initially affect the sensitivity of rhodopsin to light and may cause overactivation of visual signaling. Electrophysiological studies have demonstrated that rod cells are normally sensitive to single photons (33, 34), but two sources of noise limit the amount of light that

¹ Recipient of the Yale College Dean's Research Fellowship.

² Recipient of the Yale-Howard Hughes Medical Institute International Research Fellowship.

³ Rudolf J. Anderson Postdoctoral Fellow.

⁴ Recipient of the Research Experience for Peruvian Undergraduates, Universidad Nacional de Ingeniería, Patronato de la Universidad Nacional de Ingeniería, and Consejo Nacional de Ciencia, Tecnología e Innovación Tecnológica research fellowships.

 $⁵$ Recipient of the National Science Foundation Fellowship DGE-0644492.</sup>

⁶ Recipient of National Science Foundation CAREER Award MCB-0955407. To whom correspondence should be addressed. Tel.: 203-436-2509; Fax: 203- 432-6144; E-mail: elsa.yan@yale.edu.

 7 The abbreviations used are: RP, retinitis pigmentosa; SB, Schiff base; Meta II, metarhodopsin II; DDM, *n*-dodecyl-β-D-maltoside; Rho, rhodopsin; ERG, electroretinogram.

FIGURE 1. **Crystal structure of rhodopsin (Protein Data Bank code 1U19).** The figure shows Asp-190 and Ser-186 near the binding site of 11-*cis*-retinal. Ser-186 forms hydrogen bonds with Glu-181 and Thr-289 via two water molecules, whereas Asp-190 forms an electrostatic interaction with Arg-177 and hydrogen bonds with Arg-177, Tyr-192, Thr-193, and Asn-200. Water molecules are colored *cyan*, and *dashed yellow lines* indicate possible hydrogen bonds.

the brain can consciously detect. First, discrete dark noise refers to thermally induced false signaling that resembles the single photon response and is caused by thermal isomerization of 11-*cis*-retinal (35–37). Second, continuous dark noise refers to the constitutive activation of transducin, which can be caused by opsin not bound to retinal, a situation resulting from hydrolysis of the SB between retinal and opsin $(38-41)$. Therefore, the two kinds of dark noise are linked to the two chemical reactions, thermal isomerization and hydrolysis of SB. These two reactions comprise the thermal decay of rhodopsin (42, 43), and both reactions must be suppressed to attain the extreme photosensitivity needed for dim light vision. Thus, the thermal properties of rhodopsin are crucial to understanding the molecular etiology of RP.

We asked how the thermal stability of rhodopsin relates to the pathogenic mechanism of RP. Previous research points to the importance of a hydrogen bond network found throughout the protein in stabilizing the dark state of rhodopsin and preventing thermal isomerization of 11-*cis*-retinal (16, 42– 46). Many point mutations in rhodopsin that perturb the hydrogen bond interactions are associated with RP (21). We hypothesized that such mutations could disrupt thermal stability and raise the level of dark noise, which could be associated with the night blindness experienced by RP patients in the early stage of the disease.

We chose to study S186W (11) because it has distinct characteristics that make it a good candidate for studying the thermal properties of rhodopsin. The residue is located on extracellular loop 2, which plugs into the binding pocket of the protein (12, 16, 17). Extracellular loop 2 is home to many important molecular interactions related to photoactivation (21, 47– 49) and has been shown to play critical roles in rhodopsin stability (42– 44, 46, 50–52). Ser-186 appears to form hydrogen bonds with two conserved water molecules (Fig. 1). One water molecule may form a hydrogen bond to Thr-289 (17). The other water molecule coordinates with Glu-181 (16, 17, 45, 53), which is involved in the counterion switch mechanism that underlies the activation of rhodopsin $(47-49, 54-56)$. Ser-186 is also thought to form an intermediate interaction with the proto-

Thermal Stability of Rhodopsin and Progression of RP

nated SB in the proton transfer mechanism for switching the protonated SB counterion from Glu-113 to Glu-181 (48, 54). Another clue to the significance of Ser-186 is its proximity to Cys-187, which forms a disulfide bond with Cys-110 that is necessary for stabilizing rhodopsin; mutations that eliminate either cysteine result in moderate (C110F or C110Y) or severe RP (C187Y) (57, 58). Experiments on the nonpathogenic S186A mutation revealed that it increases the rate of thermal decay by 3-fold compared with wild type (WT) (46) and increases the rates of thermal isomerization and hydrolysis of SB by 2 orders of magnitude at 55 °C (43, 44). However, the pathogenic S186W mutant has not been characterized at the molecular level, although clinical studies suggest a severe phenotype (11, 59).

Moreover, a quantitative kinetic study of the thermal decay process of S186W has allowed a comprehensive comparison with the thermal process of the D190N mutation, which is another mutation in the rhodopsin gene that causes RP. Although the rate of thermal decay of D190N has been previously characterized (51), how this mutation affects the rate of two thermal reactions, thermal isomerization and SB hydrolysis, has not been investigated. Tsui *et al.* (60) recently reported the phenotypes of one family with the D190N mutation. Their studies revealed that the D190N genotype correlates with a relatively slow progression of RP (60), which is in contrast to the severe phenotype of the S186W mutant (11). Thus, a quantitative comparison of the kinetics of the thermal reactions of S186W and D190N will introduce a new approach to associate thermal stability of pathogenic mutants at a molecular level with vision deterioration in RP patients at a clinical level.

Similar to the S186W mutant, the D190N mutant is located on extracellular loop 2 and forms hydrogen bonds at the retinal active site. In particular, Asp-190 interacts electrostatically with Arg-177 (Fig. 1) (12, 16, 17). Using NMR, Ahuja *et al.* (21) found that Asp-190 forms hydrogen bonds with Arg-177, Ser-176, and Asn-200. X-ray crystal structures indicate that Asp-190 forms hydrogen bonds with Arg-177, Tyr-192, Thr-193, and Asn-200 (12, 16, 17). An early biochemical study by Sung *et al.* (9) reported that human D190N failed to generate lightsensitive protein, misfolded, and was retained in the endoplasmic reticulum of transfected COS cells. However, Kaushal and Khorana (61) as well as Janz *et al.* (52) found that bovine D190N had normal absorbance spectra, likely suggesting proper folding and photochemistry. Janz *et al.* (51, 52) compared the stability of dark state and Meta II in the D190N mutant with WT rhodopsin and found that the mutation increased the rate of thermal decay. Here, we aim to compare the effect of D190N with that of S186W on the thermal stability of rhodopsin to gain insight into the correlation between the thermal stability of the mutants and RP progression in patients.

To achieve this, we sought to quantitatively compare the rates of thermal reactions of S186W with those of D190N. Previously, Janz *et al.* (52) measured the rate of thermal decay of D190N and found it to be faster than that of WT rhodopsin. Here, we measured not only the rate of thermal decay but also the individual rates of thermal isomerization and the SB hydrolysis of both mutants (42– 44). Understanding the effects of the S186W and D190N mutations on individual thermally driven chemical reactions in both the dark state and active state is

FIGURE 2. **Kinetic model of the thermal processes of rhodopsin.** The model consists of two pathways. First, dark state Rho undergoes thermal isomerization at a rate $k_{\rm iso}^b$ to yield all-*trans*-retinal bound to opsin via an unprotonated SB (T^b), a Meta Il-like state. The SB in T^b breaks at a rate $k_{\rm hyd}^{\rm T}$ to yield all-*trans*-retinal free in solution (7"). Second, Rho undergoes hydrolysis of the protonated SB at a rate $k_{\rm hyd}^{\rm c}$ to form 11-*cis*-retinal free in solution (*C^f*), along with opsin protein. Then *Cf* isomerizes in the presence of opsin protein at a rate *k*iso to yield *Tf* .

critical for determining the mechanism by which these mutations give rise to visual defects. We recently proposed a kinetic model (Fig. 2) to describe the thermal processes of rhodopsin, which enables the dissection of thermal reactions into individual steps to yield their rate constants (44).

The kinetic model of the thermal decay of dark state rhodopsin (Rho) consists of two pathways. First, thermal isomerization of 11-*cis*-retinal in the binding site of rhodopsin yields all-*trans*retinal bound to opsin (T^{b}) at a rate $k_{\rm iso}^{b}$, followed by hydrolysis of the deprotonated SB to give free all-*trans*-retinal (*T^f*) at a rate k_{hyd}^T . Second, hydrolysis of the protonated SB of Rho yields free 11-*cis*-retinal (*C^f*) and opsin at a rate k_{hyd}^c , followed by opsin-catalyzed thermal isomerization of C^f to T^f at a rate k_{iso} . The thermal isomerization in the second pathway (k_{iso}) can be catalyzed by the presence of opsin, as we showed previously (44). Of the four rate constants, we can determine k_{hyd}^T experimentally using an acid denaturation assay to measure the hydrolysis of SB in activated rhodopsin. To find the remaining rate constants, we used three additional experiments as follows: UV-visible spectroscopy to measure thermal decay, HPLC analysis to measure retinal isomerization, and acid denaturation to measure hydrolysis of SB in dark state rhodopsin.

We use these three experiments because they each probe a portion of the kinetic model; combined, they elucidate each individual rate constant. The thermal decay experiment uses the absorbance at 500 nm (A_{500}) to measure the amount of dark state rhodopsin in a sample over time; thus, this experiment reflects the rate of thermal decay through both the thermal isomerization and hydrolysis pathways. Hence, the experiment measures the sum of the rates $k_{\rm iso}^b$ and $k_{\rm hyd}^c$. The HPLC experiment measures the amount of 11-*cis*-retinal present in a sample

over time (regardless of whether the retinal is bound to protein or not); thus, it is related to the rates $k_{\rm iso}^b$ and $k_{\rm iso}$. Finally, the acid denaturation experiment measures the amount of intact Schiff base present in a sample over time (regardless of the isomeric form of retinal); thus, it is related to the rates k_{hyd}^c and k_{hyd}^T . The three experiments produce three sets of data. These three sets of data combined with the independent measurement of the rate of Meta II hydrolysis (k_{hyd}^T) can be fit into the kinetic model (Fig. 2) to yield the individual rate constants, $k^c_{\rm hydro}$ $k_{\rm iso}^b$, and $k_{\rm iso}$. Thereby, we can quantitatively compare the effects of the S186W and D190N mutations on the rate of thermal isomerization and hydrolysis of SB, which are correspondingly associated with rhodopsin's discrete and continuous dark noise.

In this study, we apply the kinetic model to analyze the pathogenic rhodopsin mutations, aiming to understand the molecular etiology of RP.We studied the kinetics of thermal reactions of S186W at 37 and 55 °C and compared it with that of WT rhodopsin and D190N. The results show that the S186W mutation drastically destabilizes rhodopsin. Compared with D190N, S186W increases the rates of both thermal isomerization and hydrolysis of SB by at least an order of magnitude at 37 °C and close to 1 order of magnitude at 55 °C, which aligns with a faster pace of vision deterioration in patients carrying the S186W mutation. Hence, our results imply a potential association between the mutants' impact on thermal stability and RP progression in patients. Further quantitative studies of additional RP-causing mutants at the molecular level in conjunction with clinical studies could potentially establish a new pathogenic mechanism for RP and possibly allow for a better prognosis for this disease.

EXPERIMENTAL PROCEDURES

Materials

All chemicals were from Sigma, unless noted otherwise. Tissue culture reagents, LipofectamineTM, goat anti-mouse IgG secondary antibody conjugated to Alexa Fluor® 488 (54), and wheat germ agglutinin coupled to Alexa Fluor® 633 were purchased from Invitrogen. The surfactant DDM was from Anatrace, Inc. Synthetic oligonucleotides were from Genelink, Inc. Mouse monoclonal 1D4 antibody (62), specific to the C terminus of rhodopsin, was purchased from the University of British Columbia, and the 1D5 peptide (TETSQVAPA, corresponding to the C-terminal epitope) was synthesized by the W. M. Keck Foundation Biotechnology Resource Laboratory at Yale University.

Mutagenesis

Site-directed mutagenesis of the synthetic bovine opsin gene (63) was carried out in the expression vector pMT4. The D190N and S186W mutant opsin genes were subcloned into the pACMV-tetO vector (64, 65) with the KpnI/NotI restriction sites as described previously and confirmed by DNA sequencing.

Stable Cell Lines

WT opsin and the D190N and S186W mutants were expressed as described previously (42, 43, 54). The DNA constructs were transfected into HEK293 cells using LipofectamineTM. Transfected cells were selected using the antibiotic Geneticin (300 μ g/ml) for 2 weeks to generate a stable cell line.

Immunocytochemistry

For subcellular localization studies, HEK293 cells stably transfected with WT or mutant opsin were grown on glass coverslips. Protein expression was induced by adding tetracycline (2 μ g/ml) and sodium butyrate (5 mm) to the growth medium for 48 h. Cells were then rinsed with cold Dulbecco's phosphate-buffered saline (DPBS), and the plasma membrane was stained with wheat germ agglutinin-Alexa Fluor® 633 conjugate (10 μ g/ml) at 37 °C for 15 min. After washing the cells with cold DPBS, cells were fixed in 4% paraformaldehyde for 10 min, permeabilized with 0.02% Triton X-100 for 5 min, and blocked with 3% bovine serum albumin (BSA) in DPBS for 1 h. Cells were then incubated with mAb 1D4 (5 μ g/ml) for 1 h, blocked with 3% BSA in DPBS again, followed by a 1-h incubation with Alexa Fluor® 488-conjugated goat anti-mouse IgG (4 μ g/ml). Nucleus was then stained with Hoechst 33342 (1 μ g/ml) for 10 min. After three washes with DPBS, the coverslips were mounted on glass slides with Antifade applied. The cells were visualized with a Zeiss LSM 510 NLO META laser scanning microscope, and the images were analyzed using ImageJ. Untransfected HEK293 cells, along with WT opsin not treated with primary antibody, were used as controls.

Expression and Purification of Rhodopsin

Cells were harvested 48 h post-induction, and rhodopsin was regenerated with 5 μ m 11-*cis*-retinal overnight at 4 °C in the

FIGURE 3. **Measurement of the extinction coefficient of the protonated Schiff base.** The extinction coefficient of the protonated SB between all*trans*-retinal and acid-denatured opsin is higher than that of the protonated SB between 11-*cis*-retinal and acid-denatured opsin. At room temperature, dark state D190N rhodopsin was acid-denatured with 4 μ l of 1 m HCl and measured by UV-visible spectroscopy (*black line*), giving an extinction coefficient of 32,600 M^{-1} cm⁻¹ for the 11-*cis*-retinal SB. A second sample of D190N was light-bleached for 1 min to convert all 11-*cis*-retinal to all-*trans*-retinal. The Meta II sample was denatured and measured by UV-visible spectroscopy (*green line*), giving an extinction coefficient of 41,600 M^{-1} cm⁻¹ for the all*trans*-retinal SB.

dark. All manipulations of the regenerated rhodopsin were conducted under dim red light.

Membranes were detergent-solubilized in 50 mm Tris, 100 mm NaCl, 1 mm CaCl₂, 1% w/v DDM, 0.1 mm PMSF, pH 6.8, for 4 h at 4 °C. Rhodopsin was purified using the C-terminal 1D4 antibody coupled to Sepharose beads as described previously $(42, 43, 66, 67)$. The beads were washed three times with 50 mm Tris, 100 mM NaCl, 0.1% DDM, pH 6.8, and three times with 50 m_M sodium phosphate, 0.1% DDM, pH 6.5 (Buffer A). The rhodopsin samples were eluted in Buffer A containing 1D5 peptide for competitive binding to the antibody. The purified samples were then concentrated to ${\sim}25$ ${\mu}$ m.

UV-visible Spectroscopy

All UV-visible spectra were recorded on a Shimadzu UV-2450 spectrophotometer. The molar extinction coefficients of the D190N and S186W mutants were found at room temperature using acid denaturation of 100- μ l samples with 4 μ l of 1 M HCl (final pH 1–2) (68). The extinction coefficients of the mutants were calculated using $\epsilon_{500} = 40{,}600 \text{ m}^{-1} \text{ cm}^{-1}$ for WT rhodopsin (Fig. 3) (69).

Thermal Decay

Thermal decay of dark state rhodopsin was monitored by UV-visible spectroscopy as described previously (42, 43). Buffer A was equilibrated in a water-jacketed cuvette at 37 or 55 °C. The temperature was confirmed using a thermal couple. At $t =$ 0, ice-cold, concentrated rhodopsin solution was added to the heated buffer to give a final concentration of $1\text{--}3\ \mu$ m. UV-visible spectra were recorded over time. Samples of 200 μ l were removed from the cuvette at appropriate time points to ice-cold glass vials and stored on ice to quench thermal processes. The samples were used for two kinetic measurements, thermal isomerization and hydrolysis of the SB.

FIGURE 4. **HPLCs of the retinaloxime extracts containing the** *syn* **and** *anti* **peaks.** Over time, the concentration of 11-*cis*-retinal decreases, and the concentration of all-*trans* (and 13-*cis-*)-retinal increases.

HPLC Analysis

Retinal was extracted from the samples removed during the thermal decay experiment using the procedure described previously. Briefly, the samples were incubated on ice for 10 min with hydroxylamine, pH 7, to break the SB linkage between retinal and the opsin protein. Methanol, dichloromethane, and hexane were added to denature opsin and extract the retinaloximes. The mixture of retinaloximes was analyzed by HPLC (Beckman Coulter SYSTEM GOLD® 125 Solvent Module) on a silica column (Beckman Coulter Ultrasphere 4.6×250 mm) and a mobile phase of hexane supplemented with 8% diethyl ether and 0.33% ethanol. Absorbance at 360 nm was used for detection (Beckman Coulter SYSTEM GOLD® 168 Detector) (Fig. 4).

Acid Denaturation Assay

Samples of 100 μ l from the thermal decay experiment were denatured with HCl at pH 1–2. UV-visible spectra were immediately taken for each denatured sample at room temperature.

Hydrolysis of Schiff Base in Meta II

The experiments were performed as described previously (44). Purified rhodopsin samples were photobleached with a Fiber-Lite Illuminator Model 190, equipped with a long pass filter (>500 nm), for 1 min at 20 °C to convert dark state rhodopsin to the Meta II active form. Bleaching was confirmed by the absence of a 500-nm peak on the UV-visible absorbance spectrum. At time $t = 0$, the bleached sample was added to Buffer A incubated at 37 or 55 °C. Aliquots of 100 μ l were removed at appropriate time points, denatured using HCl at a final pH of 1–2, and analyzed by UV-visible spectroscopy.

Global Fitting

We analyzed the experimental data by global fitting (Igor Pro, version 6.2) using functions derived from our kinetic model for the thermal processes of rhodopsin (44). In our kinetic model (Fig. 2), the thermal decay of dark state rhodopsin (Rho) consists of two pathways. First, thermal isomerization of 11-*cis*-retinal in the binding site of rhodopsin yields all-*trans*retinal bound to opsin (T^b) at a rate $k_{\rm iso}^b$, followed by hydrolysis of the deprotonated SB to give free all-*trans*-retinal (*T^f*) at a rate $k_{\rm hyd}^T$. Second, hydrolysis of the protonated SB of Rho yields free 11-*cis*-retinal (*C^f*) and opsin at a rate k_{hyd}^c followed by opsincatalyzed thermal isomerization of C^f to \overline{T}^f at a rate $k_{\rm iso}$.

Based on our kinetic model, we wrote rate equations for each thermal process of rhodopsin and solved them to obtain the fitting functions for our experimental data. The detailed derivation of the equations was presented in our previous study. The fitting functions are as follows.

Hydrolysis of SB in Meta II—The ratio $[T^b]/[T^b]_0$ *is directly* proportional to the normalized A_{440} . Therefore, Equation 1 is used to fit the experimental data of SB hydrolysis in the Meta II-like activated product.

$$
\frac{\left[T^b\right]}{\left[T^b\right]_0} = e^{-k_{\text{hyd}}^T \cdot t} \tag{Eq. 1}
$$

The normalized A_{440} is plotted as a function of time, which is fitted to Equation 1 using k_{hyd}^T as fitting parameter.

Thermal Decay—The ratio [Rho]/[Rho]₀ is directly proportional to the normalized A_{500} . Therefore, Equation 2 is used to fit the experimental data of thermal decay, the normalized A_{500} plotted as a function of time.

$$
\frac{[\text{Rho}]}{[\text{Rho}]} = e^{-(k_{\text{hyd}}^{\text{C}} + k_{\text{iso}}^{\text{b}}) \cdot t}
$$
 (Eq. 2)

The fitting parameters in Equation 2 are $k^c_{\rm hyd}$ and $k^b_{\rm iso}$.

HPLC Analysis—Equation 3 is used to fit the experimental data obtained from thermal isomerization, the fraction of 11-*cis*-retinal plotted as a function of time.

$$
\frac{[11-cis]}{[Rho]_0} = \frac{k_{iso} - k_{iso}^b}{k_{iso} - (k_{hyd}^c + k_{iso}^b)} e^{-(k_{hyd}^c + k_{iso}^b) \cdot t}
$$

$$
+\frac{\frac{b_{\text{ydd}}}{k_{\text{iso}}-(k_{\text{hyd}}^C+k_{\text{iso}}^b)}e^{-k_{\text{iso}}\cdot t} \quad \text{(Eq. 3)}
$$

where [11-*cis*] is the sum of the concentration of dark state rhodopsin ([Rho]) and free 11-*cis*-retinal ([*C^f*]). The fitting parameters in Equation 3 are $k^c_{\text{hyd}}, k^b_{\text{iso}}$, and k_{iso} .

FIGURE 5. **Immunolocalization of opsin in HEK293 cells.** *a,* WT; *b,*D190N; *c,* S186W opsin; *d,* WT opsin not treated with primary antibody, and *e,* untransfected cells used as controls. The fluorescence images are side by side with the corresponding differential interference contrast (*DIC*) images; merged images are shown at *right* with the *scale bars*. The *green, red,* and *blue channels* show the opsin, plasma membrane, and nuclear staining, respectively.

Acid Denaturation Assay—Equation 4 is used to fit the experimental data of SB hydrolysis, the normalized A_{440} plotted as a function of time.

$$
\frac{[link]}{[Rho]_0} = \frac{k_{hyd}^T - k_{hyd}^C}{k_{hyd}^T - (k_{hyd}^C + k_{iso}^b)} e^{-(k_{hyd}^C + k_{iso}^b) \cdot t} + \frac{-k_{iso}^b}{k_{hyd}^T - (k_{hyd}^C + k_{iso}^b)} e^{-k_{hyd}^T \cdot t} \quad (\text{Eq. 4})
$$

where [link] is the sum of the concentration of dark state rhodopsin, [Rho], and all-*trans*-retinal bound to opsin, [*T^f*]. The ratio $[\text{link}]/[\text{Rho}]_0$ is directly proportional to the normalized A_{440} . Because k_{hyd}^T is determined independently (using Equation 1), the fitting parameters in Equation 4 are k_{hyd}^c and k_{iso}^b .

In summary, Equations 2–4 share three rate constants, k_{hyd}^c $k_{\rm iso}^b$, and $k_{\rm iso}$, which can be obtained by global fitting.

RESULTS

Immunocytochemistry—Before investigating the thermal processes of the S186W mutant and comparing them with those of WT rhodopsin and the D190N mutant, we examined the subcellular localization of the proteins to exclude misfolding and mistrafficking as the mechanism of RP for these mutations. We immunostained HEK293 cells stably transfected with the WT bovine opsin gene and the D190N and S186W mutants. Our results (Fig. 5) clearly show that the D190N and S186W opsins, similar to the WT opsin, did not form aggregate intracellularly, suggesting that the pathogenic mechanism for the mutants is not likely to be misfolding. A control of untransfected HEK293 cells (Fig. 5*e*) shows no fluorescence in the green channel.

Characterization of the S186W Mutant—The detergent-purified mutants were first characterized by UV-visible spectroscopy. All three dark state visual pigments have an absorbance maximum (λ_{max}) of 500 nm (A_{500}) and an additional peak at 280 nm corresponding to the absorbance of aromatic amino acids of opsin (A_{280}) (Fig. 6). The absorbance ratios (A_{280}/A_{500}) for WT, D190N, and S186W are 1.7, 2.2, and 2.9, respectively. We obtained the extinction coefficient using the acid denaturation method (68) . Acid denaturation with HCl at a final pH of $1-2$ yields a peak at 440 nm, indicating the presence of protonated

FIGURE 6. **UV-visible spectra of dark state (***black curve***) and acid-denatured (***green curve***) rhodopsin samples.** *a,* WT; *b,* D190N, and *c,* S186W rhodopsin. Dark state WT and mutants have absorbance maxima of 500 nm. Addition of 4 μ l of 1 M HCl reveals the protonated Schiff base, which absorbs at 440 nm. The 280-nm peak represents the absorbance of aromatic residues in the opsin protein.

FIGURE 7. **Thermal decay, UV-visible spectra of WT rhodopsin, D190N, and S186W mutants.** *a,* WT; *b,* D190N, and *c,* S186W rhodopsin at 37 °C (*top*) and 55 °C (bottom). Over time, A₅₀₀ decreases, and A₃₈₀ increases, indicating thermal decay. *d*, normalized A₅₀₀ plotted as a function of time. The fitted curve is added to guide the visualization of the decay trend.

SB (70), for which we calculate the extinction coefficient to be $32{,}600$ M $^{-1}$ cm $^{-1}$. From this value, the extinction coefficients of D190N and S186W rhodopsin were determined to be 38,000 and 36,300 M^{-1} cm⁻¹, respectively (maximum errors of 10%), compared with 40,600 M^{-1} cm⁻¹ for WT rhodopsin (69).

Thermal Decay—After spectral characterization of WT and mutant rhodopsin samples, we measured their rate of thermal decay, defined as the decrease of the 500-nm absorbance, at 37 and 55 °C. To initiate thermal decay, at time $t = 0$, purified rhodopsin was incubated at 37 or 55 °C. A series of UV-visible absorption spectra were obtained at various time points (Fig. 7, $a-c$). Over time, the A_{500} indicating dark state rhodopsin decreases, whereas the A_{380} increases due to the formation of free 11-*cis*-retinal (k^c_{hyd}), all-*trans*-retinal bound to opsin (k^b_{iso}), and/or free all-*trans*-retinal (k_{hyd}^T) . The spectra were normalized to the A_{280} to account for solvent evaporation and to the A_{500} at $t = 0$. The normalized A_{500} was plotted as a function of time (Fig. 7*d*). Although the kinetics of thermal decay for WT and D190N at 37 °C are too slow to monitor for completion under our experimental conditions, the half-lives were ob-

tained by analyzing the initial slope and found to be 15 \pm 1 and 7.0 ± 0.5 days for WT and D190N, respectively. In contrast, the S186W mutant undergoes complete decay in \sim 8 h. Fitting the decay curve yields a half-life of 37 \pm 1 min. However, at 55 °C, both the D190N and S186W mutations speed up the thermal decay process significantly compared with the WT (Fig. 7). The half-lives for S186W, D190N, and WT rhodopsin are 0.39 \pm 0.01, 2.42 \pm 0.05, and 70 \pm 2 min, respectively. The thermal decay rate of S186W is 179 times faster than that of WT rhodopsin and 6.2 times faster than that of D190N at 55 °C.

HPLC Analysis—We then turned to the two components of thermal decay (Fig. 2), thermal isomerization and hydrolysis of SB. We used HPLC analysis to monitor the isomerization of both bound and free retinal in the samples of rhodopsin incubated at 37 and 55 °C. Fig. 8, *a*–*c,* shows the chromatographs of the HPLC analyses of the thermal decay products. Six isomers of retinaloxime were detected in order of appearance on the chromatograph as follows: they are 11-*cis*-15-*syn*, all-*trans*-15 *syn*, 13-*cis*-15-*syn*, 13-*cis*-15-*anti*, 11-*cis*-15-*anti*, and all-*trans*-15-*anti*, as presented in the Fig. 4. Only the *syn* peaks are shown

FIGURE 8. **Thermal isomerization, HPLC analysis ofWT rhodopsin, D190N, and S186W mutants.** *a,* WT; *b,*D190N, and *c,* S186W rhodopsin at 37 °C (*top*) and 55 °C (*bottom*). Over time, the concentration of 11-*cis*-retinal decreases, and the concentration of all-*trans-* and 13-*cis-*retinal increases, indicating isomerization. *d,* normalized concentration of 11-*cis*-retinal plotted as a function of time. The fitted curve is added to guide the visualization of the decay trend.

in Fig. 8 for clarity because they are the predominant peaks. The peaks were fit into a Gaussian function to determine peak areas, which were then calibrated to the corresponding molar extinction coefficients at 360 nm (71). Over time, the 11-*cis*-retinal peak decreases, and the all-*trans* peak increases due to thermal isomerization of bound 11 -*cis*-retinal (k_{iso}^b) and/or isomerization of free 11-*cis*-retinal in the presence of opsin (k_{iso}) , as described in the kinetic model (Fig. 2). The fraction of 11-*cis*retinal in each sample was plotted over time (Fig. 8*d*). At 37 °C, the trend of thermal isomerization agrees with that of thermal decay: WT rhodopsin barely isomerizes and D190N isomerizes slightly faster than WT, whereas S186W isomerizes considerably faster than WT rhodopsin and D190N (quantitative analysis for the rate constants will be presented below). At 55 °C, although both the D190N and S186W mutations increase the rate of thermal isomerization, S186W has a larger effect than D190N (Fig. 8*d, inset*).

Acid Denaturation Assay—To study the second pathway of thermal decay, hydrolysis of the SB (Fig. 2), we used an acid denaturation assay to measure the amount of intact SB in thermal decay samples over time. UV-visible spectra were taken for each denatured sample at room temperature (Fig. 9, *a*–*c*). The spectra were fit into two Gaussian functions to obtain the A_{440} , characteristic of an intact protonated SB, and the A_{380} , characteristic of free retinal after hydrolysis of the SB. The A_{440} decreases and the *A*³⁸⁰ increases due to hydrolysis of 11-*cis*retinal from dark state rhodopsin (k_{hyd}^c) and/or hydrolysis of all-*trans*-retinal from activated rhodopsin (k_{hyd}^T) . The A_{440} , normalized to the A_{440} at $t = 0$, was plotted over time (Fig. 9*d*). Interestingly, just like the rate of thermal isomerization increases more for S186W than for D190N, the rate of SB hydrolysis also increases in the same pattern, suggesting that

the isomerization and hydrolysis pathways are both affected by the mutations, and S186W has a larger effect. Similarly, at 37 °C, the drop of the 440-nm peak for S186W is orders of magnitude faster than that for WT rhodopsin and the D190N mutant. The 440-nm peak for the D190N samples does not change within experimental error after incubation for 20–25 h. Quantitative analysis of the rates by fitting the data into the kinetic model (Fig. 2) will be presented below.

Hydrolysis of Schiff Base in Meta II—As reported previously (44), to use the kinetic model (Fig. 2) to analyze the kinetic data obtained from the above three experiments, thermal decay, thermal isomerization, and hydrolysis of SB, we need to independently measure the rate of hydrolysis of SB in the activated intermediate, k_{hyd}^T (Fig. 2). To do so, a purified sample was photobleached for 1 min so that the 500-nm peak for the dark state completely transitioned to the 380-nm peak for Meta II. The bleached sample was then incubated at 37 or 55 °C. Aliquots were taken over time and denatured by HCl. UV-visible spectra were taken for each denatured sample (Fig. 10, *a*–*c*). The spectra were fit into two Gaussian functions to obtain the A_{440} , which represents all-*trans*-retinal bound to opsin, and A_{380} , which corresponds to free all-*trans*-retinal after hydrolysis. Over time, the 440-nm peak decreases and the 380-nm peak increases, indicating the hydrolysis of the SB. The A_{440} , normalized to the A_{440} at $t = 0$, was plotted over time (Fig. 10*d*). In contrast to the large increase in dark state reaction rates, our results show that the D190N and S186W mutants have little impact on SB hydrolysis in the active state. At 37 °C, the D190N mutation accelerates k_{hyd}^T by just 1.7 times the WT rate. S186W has an approximately equal but opposite effect; it slows k_{hyd}^T by 1.6 times. At 55 °C, k_{hyd}^T is the same for WT and S186W, and D190N is 1.2-fold slower.

FIGURE 9.**Hydrolysis of Schiff base in rhodopsin, acid denaturation assay for WT rhodopsin, D190N, and S186W mutants.** *a,* WT; *b,*D190N, and *c,* S186W rhodopsin at 37 °C (*top*) and 55 °C (*bottom*). Over time, *A*⁴⁴⁰ decreases, and *A*³⁸⁰ increases, indicating hydrolysis of the SB. *d,* normalized *A*⁴⁴⁰ plotted as a function of time. The fitted curve is added to guide the visualization of the decay trend.

FIGURE 10. **Hydrolysis of Schiff base in Meta II-like activated product, acid denaturation assay for activated WT rhodopsin, D190N, and S186W mutants.** *a,* WT; *b,* D190N, and *c,* S186W rhodopsin at 37 °C (*top*) and 55 °C (*bottom*). Over time, *A*⁴⁴⁰ decreases, and *A*³⁸⁰ increases, indicating hydrolysis of SB. *d,* normalized A_{440} plotted as a function of time and fit to obtain the rate constant $k_{\rm hydro}^{T}$

Rate Constants of Individual Thermal Processes—To obtain the individual rate constants k_{hyd}^c , k_{iso}^b , and k_{iso} , we used the solution of the kinetic model (44) to analyze the kinetic data. We measured the rates of hydrolysis of SB in Meta II by fitting data shown in Fig. 10*d* with a single exponential function to obtain k_{hyd}^T . Then, we performed global fitting of the kinetic data obtained in the experiments of thermal decay (Fig. 7*d*), thermal isomerization (Fig. 8*d*), and hydrolysis of SB (Fig. 9*d*) for WT, D190N, and S186W at 55 °C and for S186W at 37 °C. Because we repeated each kinetic measurement at least three times, we did global fitting to replicates of the same condition together and reported the fitting parameters in Table 1. In deriving the equation for analyzing the kinetic data of SB hydrolysis (acid denaturation) for dark state rhodopsin, we made an assumption that the error of quantifying the intact SB in rhodopsin due to the difference in the extinction coefficients

TABLE 1 **Rate constants and half-lives (S.D.) of thermal processes of WT rhodopsin, D190N, and S186W mutants**

All experiments were performed 3–5 times.

of the 11-*cis* (ϵ_{cis}) and all-*trans*-retinal chromophore (ϵ_{trans}) is negligible. Detailed verification of this assumption can be found under the "Discussion." We did not use the kinetic model to analyze the data for WT and D190N at 37 °C because the decay rates are too slow to be measured. The half-lives of thermal decay were found to be 15 and 7 days. Because of solvent evaporation, the full decay cannot be measured in our experiments. Therefore, we focused on analyzing the kinetic data for WT, D190N, and S186W at 55 °C and S186W at 37 °C. The results of one representative global fitting are shown in Fig. 11, and the rate constants obtained from global fittings are presented in Table 1. Thus, we can quantitatively explore the thermal properties of S186W and compare the effects of S186W with those of D190N on the kinetics of thermal reactions.

DISCUSSION

This work focuses on the pathogenic S186W mutation in the rhodopsin gene. Although the S186W mutation is associated with RP, it has not been previously characterized at the molecular level. Our study provides a quantitative description of the effects of the S186W mutation on the thermal properties of rhodopsin. This work also supplements the previous study on the thermal decay of the D190N mutant by investigating the effects of D190N on the rates of individual thermal reactions involved in thermal decay, thermal isomerization and SB hydrolysis. Our study introduces a new approach for molecular level studies of pathogenic rhodopsin mutations to show the effect of mutations on individual thermal reactions of rhodopsin. These individual reactions set the limit of sensitivity of dimlight vision. Hence, a quantitative comparison of their rates for S186W and D190N allows for a fundamental understanding of the mutations' effects on the thermal stability of rhodopsin and correlation of these effects with the pace of disease progression in RP patients.

Mutant Rhodopsins Localize to Membrane—We observed that WT and mutant opsins traffic to the plasma membrane in HEK293 cells, suggesting that the proteins are properly folded to an extent that cells are able to tolerate the mutations and transport the opsin to the plasma membrane. Studies of D190N folding, localization, and photoactivity have been performed in bovine, murine, and human rhodopsin with sometimes differing results, so the question of folding should be interpreted with caution until it can be definitively answered in a human model. Although previous*in vitro* studies showed human D190N to be misfolded and retained in the endoplasmic reticulum, the recent development of a knock-in mouse model heterozygous for the murine D190N mutation faithfully recapitulates the features of human disease and showed that the mutant rhodopsin indeed localizes to the membrane (72). Moreover, we could purify the bovine D190N and S186W mutants and show its activation in response to photobleaching, which attests that the D190N and S186W mutants retainWT-like function. Although the mutants had a higher A_{280}/A_{500} ratio than WT rhodopsin, this was likely due to the change in the binding site, such that mutant opsin may not be regenerated to form visual pigment as efficiently as WT opsin under our experimental conditions; it is also possible that a small amount of thermal bleaching occurred during sample preparation. Thus, our experimental results together with the previous animal model study (72) indicate that, although the mutations necessarily change the protein structure at the molecular level, the structural changes are tolerated at the cellular level, so misfolding or mistrafficking is not likely to be the predominant molecular mechanism of RP for these mutations. Instead, we hypothesized that the RP genotypes are associated with thermal destabilization of rhodopsin.

Rate of SB Hydrolysis, Difference in Extinction Coefficients— In analyzing the rate of hydrolysis of SB in dark state rhodopsin, we made an assumption that the error of quantifying the intact SB in rhodopsin due to the difference in the extinction coefficients of the $11\text{-}cis(\epsilon_{cis})$ and all-*trans*-retinal chromophore(ϵ_{trans}) is negligible. Here, we verify this assumption. In the kinetic model, two thermal processes involve SB hydrolysis as follows: 1) hydrolysis of the pro- ϵ tonated SB of Rho at a rate k_{hyd}^c to form C , and 2) hydrolysis of the deprotonated SB of T^b at a rate k_{hyd}^T to form T^f . The concentration of species containing an intact SB (link) is determined by UVvisible absorption spectroscopy in the acid denaturation experiment (Equation 5).

$$
A_{440 \text{ nm}} = \epsilon_{\text{cis}}[\text{Rho}]I + \epsilon_{\text{trans}}[T^b]I
$$

$$
[link] = \frac{A_{440 \text{ nm}}}{\epsilon_{cis}J} = [Rho] + \frac{\epsilon_{trans}}{\epsilon_{cis}}[T^b] \quad (\text{Eq. 5})
$$

Hence, we get Equation 6.

$$
-\frac{d[link]}{dt} = k_{\text{hyd}}^{c}[Rho] + k_{\text{hyd}}^{T} \frac{\epsilon_{trans}}{\epsilon_{cis}} [T^{b}] = k_{\text{hyd}}^{c}[Rho]
$$

$$
+\left(k_{\text{hyd}}^{T} \frac{\epsilon_{trans}}{\epsilon_{cis}}\right) ([link] - [Rho]) = \left(k_{\text{hyd}}^{c} - k_{\text{hyd}}^{T} \frac{\epsilon_{trans}}{\epsilon_{cis}}\right) [Rho]
$$

$$
+ k_{\text{hyd}}^{T} \frac{\epsilon_{trans}}{\epsilon_{cis}} [link] \quad (\text{Eq. 6})
$$

Substituting [Rho] from Equation 2, we obtain Equations 7–9.

FIGURE 11. **Global fitting of kinetic data for the thermal processes of WT rhodopsin, D190N, and S186W mutants.** *a,* WT rhodopsin at 55 °C; *b,* D190N at 55 °C; *c,* S186W at 55 °C, and *d,* S186W at 37 °C. The results of thermal decay (*black*) are shown as the normalized *A*⁵⁰⁰ plotted as a function of time. Theresults ofHPLC analysis(*blue*) are shown as the concentration of 11-*cis*-retinal plotted over time. The results of the acid denaturation assay(*red*) are shown as the normalized A₄₄₀ plotted as a function of time. Global fitting was used to obtain the rate constants of individual thermal processes, which are presented in Table 1.

(Eq. 7)

$$
-\frac{d[link]}{dt} = \left(k_{\text{hyd}}^C - k_{\text{hyd}}^T \frac{\epsilon_{trans}}{\epsilon_{cis}}\right)[Rho]_0 e^{-(k_{\text{hyd}}^C + k_{\text{iso}}^b) \cdot t} + k_{\text{hyd}}^T \frac{\epsilon_{trans}}{\epsilon_{cis}}[link]
$$

$$
\begin{aligned} [\text{link}] &= \frac{\left(k_{\text{hyd}}^T \frac{\epsilon_{trans}}{\epsilon_{cis}} - k_{\text{hyd}}^C\right) [\text{Rho}]_0}{k_{\text{hyd}}^T \frac{\epsilon_{trans}}{\epsilon_{cis}} - (k_{\text{hyd}}^C + k_{\text{iso}}^b)} e^{-(k_{\text{hyd}}^C + k_{\text{iso}}^b) \cdot t} \\ &- k_{\text{hyd}}^b \frac{\epsilon_{trans}}{\epsilon_{cis}} - k_{\text{hyd}}^b \text{ [Rho]} \end{aligned}
$$

$$
+\frac{-k_{\text{iso}}^b[\text{Rho}]_0}{k_{\text{hyd}}^T \frac{\epsilon_{trans}}{\epsilon_{cis}} - (k_{\text{hyd}}^c + k_{\text{iso}}^b)} e^{-k_{\text{hyd}}^T \frac{\epsilon_{trans}}{\epsilon_{cis}} \cdot t} \quad (\text{Eq. 8})
$$

$$
\begin{split} [\text{link}] &= \frac{(k_{\text{hyd}}^T - k_{\text{hyd}}^C) [\text{Rho}]_0}{k_{\text{hyd}}^T - (k_{\text{hyd}}^C + k_{\text{iso}}^b)} e^{-(k_{\text{hyd}}^C + k_{\text{iso}}^b) \cdot t} \\ &+ \frac{-k_{\text{iso}}^b [\text{Rho}]_0}{k_{\text{hyd}}^T - (k_{\text{hyd}}^C + k_{\text{iso}}^b)} e^{-k_{\text{hyd}}^T \cdot t} \quad (\text{Eq. 9}) \end{split}
$$

Equation 8 is the fitting function for analyzing the rate of SB hydrolysis when the difference in ϵ_{trans} and ϵ_{cis} is taken into consideration. However, Equation 9 is the fitting function when the difference is neglected, as presented in our previous study (44). Comparing Equations 8 and 9, we can see that there is an additional constant of $\epsilon_{trans}/\epsilon_{cis}$ in the new equation.

By using the new fitting function (Equation 8), all rate constants are obtained and listed in parentheses in Table 2, alongside the rates reported in Table 1, which were calculated without consideration of the difference in extinction coefficients. The k_{hyd}^T rate constant is obtained by independent experiment, so one value is used in both cases. Within experimental error, the rate constants obtained using both Equations 8 and 9 are the same. Hence, although we assume that there is negligible error in quantifying the intact SB in dark state rhodopsin due to the difference in the extinction coefficients of 11-*cis*-retinal (ϵ_{cis}) and all-*trans*-retinal (ϵ_{trans}), this assumption is valid.

Comparison of Thermal Kinetics of S186W at 37 and 55 °C— To investigate the effects of S186W on the thermal properties of rhodopsin, we obtained the individual rate constants of thermal isomerization ($k_{\rm iso}^b$) and hydrolysis of SB in dark state ($k_{\rm hyd}^c$) by applying our kinetic model at 37 and 55 °C. Hence, we can quantitatively compare the individual rates of thermal isomerization and SB hydrolysis of S186W at the two different temperatures, 37 and 55 °C (Table 1), which reveals two characteristic impacts of S186W on the kinetics of thermal reactions. First, when temperature increases from 37 to 55 °C, the rate

TABLE 2

Rate constants and half-lives (S.D.) of thermal processes of WT rhodopsin, D190N, and S186W mutants after accounting for the difference between *trans* **and** *cis*

constants of thermal isomerization ($k_{\rm iso}^b$) and SB hydrolysis (k_{hyd}^c) increase by 517 and 15 times, respectively. From this temperature dependence, the activation energies of thermal isomerization and SB hydrolysis can be roughly estimated to be 70 and 30 kcal/mol, respectively. Although these are large activation energies, they are not as high as those for WT thermal isomerization (125 kcal/mol) and SB hydrolysis (122 kcal/mol), which were obtained at temperatures around 55 °C (44). Second, at 37 °C, thermal isomerization accounts for 14 \pm 3% of the thermal decay of the S186W, whereas SB hydrolysis accounts for 86 \pm 5% (Table 1). These contributions change at 55 °C to 86 \pm 4% for thermal isomerization and $14 \pm 2\%$ for SB hydrolysis. The shift in contributions reflects the difference in the activation energies of the two reactions. Because the process of thermal isomerization has higher activation energy, the contribution of thermal isomerization to the overall thermal decay process becomes more significant at a higher temperature (55 °C).

Rates of Thermal Isomerization and SB Hydrolysis of S186W, D190N, and WT—We studied the kinetics of thermal decay of S186W and compared it with that of WT and D190N. At 37 °C, we observed that S186W thermally decays 2 orders of magnitude faster than D190N and 3 orders of magnitude faster than WT under our experimental conditions.

The thermal decay half-lives for the D190N mutant and WT rhodopsin at 55 °C were previously measured by Janz and Farrens (52). They found that the half-lives of WT rhodopsin and D190N are 38.5 ± 3 and 2.4 ± 0.4 min, in qualitative agreement with our results. The observed differences in rate could be due to a slight difference in temperature control because the high activation energy of WT thermal decay suggests that a deviation of 1 °C in maintaining the temperature at 55 °C could lead to an \sim 2-fold difference in the rates.

We further compared the rate constants of thermal isomerization ($k^b_{\rm iso}$) and hydrolysis of SB in dark state ($k^c_{\rm hyd}$) of S186W, D190N, and WT rhodopsin at 55 °C. Although running the experiment at 55 °C is not physiologically relevant, this higher temperature allowed us to analyze quantitatively the rates of thermal reactionsin D190N for a direct comparison with S186W. Such analysis clearly shows that the impact of S186W on both thermal isomerization and SB hydrolysis in dark state rhodopsin is larger than that of D190N under our experimental conditions.

Mutant Effects on Dark State Versus Active State—Moreover, our results demonstrate that the mutations, which specifically perturb the hydrogen bond network of rhodopsin, increase the rate of thermal isomerization and hydrolysis of SB (the dark state thermal reactions that contribute to thermal decay) without greatly affecting the stability of the photoactivated state or the ability of opsin to catalyze isomerization of free 11-*cis*-retinal. Unlike the kinetics of thermal processes in the dark state, the rate of SB hydrolysis in the Meta II-like photo-product (k_{hyd}^T) is within 2-fold of WT rhodopsin at both 37 and 55 °C. Hence, the hydrogen bond network likely exerts its stabilizing influence on dark state rhodopsin and is much less important after activation.

Association of Thermal Stability and Early Symptoms of RP— Our characterization of the thermal properties of the S186W and D190N mutations reveals an association between the thermal stability of rhodopsin and the early symptoms of RP. Normally, the hydrogen bond network of WT rhodopsin minimizes discrete dark noise by preventing thermal isomerization and suppresses constitutive activation by preventing hydrolysis of SB (16, 42, 43, 51, 53, 73). When mutations eliminate interactions in the hydrogen bond network, these restraints are weakened. Even a slight increase in the rates of thermal isomerization or SB hydrolysis would be greatly magnified by the abundance of rhodopsin in the eye, *i.e.* $\sim 10^{16}$ molecules per human eye. Thus, the increased rates of thermal isomerization and hydrolysis of SB in the S186W and D190N mutants likely correlate with a higher threshold of light intensity needed for vision and the early symptom of night blindness in RP. In addition, up to 35% of RP patients experience photopsia, the false flashes of light seen in the early stages of the disease (6, 32). The elevated continuous and discrete dark noise related to thermal destabilization could be associated with photopsia as well as night blindness.

Clinical Studies, Comparison of S186W and D190N—Most clinical studies reporting the phenotypes of patients affected by S186W and D190N describe features such as visual acuity, visual field, fundoscopy, and ERG responses. However, it is difficult to compare the phenotypes of S186W and D190N patients in terms of visual acuity, visual field, and fundoscopy, because various reports provide varying degrees of detail. Hence, we focused on the quantitative comparison of ERG responses. Ruther *et al.* (11) and Matias-Florentino *et al.* (59) have reported cases of 30- and 36-year-old S186W-affected patients, respectively, who had either barely recordable or completely abolished ERGs. However, Fishman *et al.* (74) reported that D190N-affected patients at ages of 36 and 80 years had ERGs with delayed but still detectable responses. Additionally, Tsui *et al.* (60) reported a D190N-affected patient who at 47 years of age had a reduced ERG response, which continued to decrease at a rate of about 3% per year but remained recordable. This comparison indicates that S186W patients seem to experience more severe symptoms of RP at younger ages than D190N patients, pointing to a faster rate of disease progression in S186W patients. Moreover, Ruther *et al.* (11) reported an

S186W-affected patient who presented with greatly reduced rod ERGs at the age of 6 years. Meanwhile, Tsui *et al.* (60) reported two patients aged 7 and 11 who carried the D190N mutation but were clinically asymptomatic. This further demonstrates that S186W causes earlier presentation as well as faster progression of RP compared with D190N.

Thermal Stability and RP Progression of S186W and D190N— Our molecular studies allow for a comprehensive comparison of the impacts of the S186W and D190N mutations on the kinetics of thermal reactions of dark state rhodopsin. Although our experimental conditions are far from resembling the complex cellular environments of rod photoreceptor cells, our kinetic studies clearly reveal the differences in the intrinsic thermal properties of S186W and D190N at the molecular level. The S186W mutant has a much stronger impact on the thermal stability of rhodopsin, which is qualitatively consistent with the faster progression of RP in patients bearing the S186W mutation. A quantitative correlation, if one exists, remains to be found when these studies can be expanded to a larger number of RP-causing mutants.

Significance of Molecular Level Characterizations—To fully elucidate the etiology of retinal degenerative diseases will require more research on all points of the biological spectrum of understanding, from clinical reports to animal models, cellular systems, and molecular details. Our molecular studies enable the expansion of this spectrum to a level of detail not before possible, kinetic measurements of the individual chemical pathways underlying the thermal activation of rhodopsin. Extending our experimental approach to a systematic study of other pathogenic mutations, in conjunction with clinical research, holds promise to uncover knowledge that would help improve the prognosis of RP patients.

Acknowledgments—We thank Dr. Joseph Wolenski for assistance with confocal microscopy and Dr. Phillip Reeves (University of Essex) for the HEK293 cells and pACMV-tetO expression vector. We also thank Dr. Ching-Hwa Sung (Weill Medical College of Cornell University) for providing the B6 –30 antibody in the preliminary immunofluorescence experiments on HEK293 cells.

REFERENCES

- 1. Shastry, B. S. (1994) Retinitis pigmentosa and related disorders: phenotypes of rhodopsin and peripherin/RDS mutations. *Am. J. Med. Genet.* **52,** 467–474
- 2. Berson, E. L. (1996) Retinitis pigmentosa: unfolding its mystery. *Proc. Natl. Acad. Sci. U.S.A.* **93,** 4526–4528
- 3. Kalloniatis, M., and Fletcher, E. L. (2004) Retinitis pigmentosa: understanding the clinical presentation, mechanisms, and treatment options. *Clin. Exp. Optom.* **87,** 65–80
- 4. Kennan, A., Aherne, A., and Humphries, P. (2005) Light in retinitis pigmentosa. *Trends Genet.* **21,** 103–110
- 5. Hartong, D. T., Berson, E. L., and Dryja, T. P. (2006) Retinitis pigmentosa. *Lancet* **368,** 1795–1809
- 6. Shintani, K., Shechtman, D. L., and Gurwood, A. S. (2009) Review and update: current treatment trends for patients with retinitis pigmentosa. *Optometry* **80,** 384–401
- 7. Rakoczy, E. P., Kiel, C., McKeone, R., Stricher, F., and Serrano, L. (2011) Analysis of disease-linked rhodopsin mutations based on structure, function, and protein stability calculations. *J. Mol. Biol.* **405,** 584–606
- 8. Sung, C. H., Schneider, B. G., Agarwal, N., Papermaster, D. S., and Na-

thans, J. (1991) Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. *Proc. Natl. Acad. Sci. U.S.A.* **88,** 8840–8844

- 9. Sung, C. H., Davenport, C. M., and Nathans, J. (1993) Rhodopsin mutations responsible for autosomal dominant retinitis pigmentosa. Clustering of functional classes along the polypeptide chain. *J. Biol. Chem.* **268,** 26645–26649
- 10. Mendes, H. F., van der Spuy, J., Chapple, J. P., and Cheetham, M. E. (2005) Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. *Trends Mol. Med.* **11,** 177–185
- 11. Ruther, K., vonBallestrem, C. L., Muller, A., Kremmer, S., Eckstein, A., ApfelstedtSylla, E., Gal, A., and Zrenner, E. (1995) in *Clinical Features of Autosomal Dominant Retinitis Pigmentosa Associated with the SER 186TRP Mutation of Rhodopsin* (Anderson, R. E., LaVail, M. M., and Hollyfield, J. G., eds) pp. 303–312, Plenum Publishing Corp., New York
- 12. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le Trong, I., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M., and Miyano, M. (2000) Crystal structure of rhodopsin: A G proteincoupled receptor. *Science* **289,** 739–745
- 13. Menon, S. T., Han, M., and Sakmar, T. P. (2001) Rhodopsin: structural basis of molecular physiology. *Physiol. Rev.* **81,** 1659–1688
- 14. Okada, T., Ernst, O. P., Palczewski, K., and Hofmann, K. P. (2001) Activation of rhodopsin: new insights from structural and biochemical studies. *Trends Biochem. Sci.* **26,** 318–324
- 15. Filipek, S., Stenkamp, R. E., Teller, D. C., and Palczewski, K. (2003) G protein-coupled receptor rhodopsin: a prospectus. *Annu. Rev. Physiol.* **65,** 851–879
- 16. Li, J., Edwards, P. C., Burghammer, M., Villa, C., and Schertler, G. F. (2004) Structure of bovine rhodopsin in a trigonal crystal form. *J. Mol. Biol.* **343,** 1409–1438
- 17. Okada, T., Sugihara, M., Bondar, A. N., Elstner, M., Entel, P., and Buss, V. (2004) The retinal conformation and its environment in rhodopsin in light of a new 2.2 Å crystal structure. *J. Mol. Biol.* **342,** 571–583
- 18. Palczewski, K. (2006) G protein-coupled receptor rhodopsin. *Annu. Rev. Biochem.* **75,** 743–767
- 19. Ridge, K. D., and Palczewski, K. (2007) Visual rhodopsin sees the light: structure and mechanism of G protein signaling. *J. Biol. Chem.* **282,** 9297–9301
- 20. Gleim, S., and Hwa, J. (2008) in *Visual Transduction and Non-visual Light Perception* (Tombran-Tink, J., and Barnstable, C. J., eds) pp. 171–196, Humana Press Inc., Totowa, NJ
- 21. Ahuja, S., Hornak, V., Yan, E. C., Syrett, N., Goncalves, J. A., Hirshfeld, A., Ziliox, M., Sakmar, T. P., Sheves, M., Reeves, P. J., Smith, S. O., and Eilers, M. (2009) Helix movement is coupled to displacement of the second extracellular loop in rhodopsin activation. *Nat. Struct. Mol. Biol.* **16,** 168–175
- 22. Papermaster, D. S., and Dreyer, W. J. (1974) Rhodopsin content in the outer segment membranes of bovine and frog retinal rods. *Biochemistry* **13,** 2438–2444
- 23. Hubbard, R., and Wald, G. (1951) The mechanism of rhodopsin synthesis. *Proc. Natl. Acad. Sci. U.S.A.* **37,** 69–79
- 24. Hug, S. J., Lewis, J. W., Einterz, C. M., Thorgeirsson, T. E., and Kliger, D. S. (1990) Nanosecond photolysis of rhodopsin: evidence for a new, blueshifted intermediate. *Biochemistry* **29,** 1475–1485
- 25. Randall, C. E., Lewis, J. W., Hug, S. J., Bjorling, S. C., Eisnershanas, I., Friedman, N., Ottolenghi, M., Sheves, M., and Kliger, D. S. (1991) *J. Am. Chem. Soc.* **113,** 3473–3485
- 26. Schoenlein, R. W., Peteanu, L. A., Mathies, R. A., and Shank, C. V. (1991) The first step in vision: femtosecond isomerization of rhodopsin. *Science* **254,** 412–415
- 27. Pan, D., Ganim, Z., Kim, J. E., Verhoeven, M. A., Lugtenburg, J., and Mathies, R. A. (2002) Time-resolved resonance Raman analysis of chromophore structural changes in the formation and decay of rhodopsin's BSI intermediate. *J. Am. Chem. Soc.* **124,** 4857–4864
- 28. Lüdeke, S., Lórenz Fonfría, V. A., Siebert, F., and Vogel, R. (2006) Timeresolved rapid-scan Fourier transform infrared difference spectroscopy on a noncyclic photosystem: rhodopsin photointermediates from Lumi to Meta II. *Biopolymers* **83,** 159–169

- 29. Smith, S. O. (2010) Structure and activation of the visual pigment rhodopsin. *Annu. Rev. Biophys.* **39,** 309–328
- 30. Fung, B. K., Hurley, J. B., and Stryer, L. (1981) Flow of information in the light-triggered cyclic nucleotide cascade of vision. *Proc. Natl. Acad. Sci. U.S.A.* **78,** 152–156
- 31. Burns, M. E., and Arshavsky, V. Y. (2005) Beyond counting photons: trials and trends in vertebrate visual transduction. *Neuron* **48,** 387–401
- 32. Bhatti, M. T. (2006) Retinitis pigmentosa, pigmentary retinopathies, and neurologic diseases. *Curr. Neurol. Neurosci. Rep.* **6,** 403–413
- 33. Barlow, H. B. (1956) Retinal noise and absolute threshold. *J. Opt. Soc. Am.* **46,** 634–639
- 34. Baylor, D. A., Lamb, T. D., and Yau, K. W. (1979) Responses of retinal rods to single photons. *J. Physiol.* **288,** 613–634
- 35. Ashmore, J. F., and Falk, G. (1977) Dark noise in retinal bipolar cells and stability of rhodopsin in rods. *Nature* **270,** 69–71
- 36. Baylor, D. A., Matthews, G., and Yau, K. W. (1980) Two components of electrical dark noise in toad retinal rod outer segments. *J. Physiol.* **309,** 591–621
- 37. Luo, D. G., Yue, W. W., Ala-Laurila, P., and Yau, K. W. (2011) Activation of visual pigments by light and heat. *Science* **332,** 1307–1312
- 38. Robinson, P. R., Cohen, G. B., Zhukovsky, E. A., and Oprian, D. D. (1992) Constitutively active mutants of rhodopsin. *Neuron* **9,** 719–725
- 39. Dryja, T. P., Berson, E. L., Rao, V. R., and Oprian, D. D. (1993) Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness. *Nat. Genet.* **4,** 280–283
- 40. Rao, V. R., Cohen, G. B., and Oprian, D. D. (1994) Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness. *Nature* **367,** 639–642
- 41. Cohen, G. B., Yang, T., Robinson, P. R., and Oprian, D. D. (1993) Constitutive activation of opsin: influence of charge at position 134 and size at position 296. *Biochemistry* **32,** 6111–6115
- 42. Liu, J., Liu, M. Y., Nguyen, J. B., Bhagat, A., Mooney, V., and Yan, E. C. (2009) Thermal decay of rhodopsin: role of hydrogen bonds in thermal isomerization of 11-*cis*-retinal in the binding site and hydrolysis of protonated Schiff base. *J. Am. Chem. Soc.* **131,** 8750–8751
- 43. Liu, J., Liu, M. Y., Nguyen, J. B., Bhagat, A., Mooney, V., and Yan, E. C. (2011) Thermal properties of rhodopsin: insight into the molecular mechanism of dim-light vision. *J. Biol. Chem.* **286,** 27622–27629
- 44. Liu, J., Liu, M. Y., Fu, L., Zhu, G. A., and Yan, E. C. (2011) Chemical kinetic analysis of thermal decay of rhodopsin reveals unusual energetics of thermal isomerization and hydrolysis of Schiff base. *J. Biol. Chem.* **286,** 38408–38416
- 45. Okada, T., Fujiyoshi, Y., Silow, M., Navarro, J., Landau, E. M., and Shichida, Y. (2002) Functional role of internal water molecules in rhodopsin revealed by x-ray crystallography. *Proc. Natl. Acad. Sci. U.S.A.* **99,** 5982–5987
- 46. Janz, J. M., and Farrens, D. L. (2004) Role of the retinal hydrogen bond network in rhodopsin Schiff base stability and hydrolysis. *J. Biol. Chem.* **279,** 55886–55894
- 47. Yan, E. C., Kazmi, M. A., De, S., Chang, B. S., Seibert, C., Marin, E. P., Mathies, R. A., and Sakmar, T. P. (2002) Function of extracellular loop 2 in rhodopsin: glutamic acid 181 modulates stability and absorption wavelength of metarhodopsin II. *Biochemistry* **41,** 3620–3627
- 48. Yan, E. C., Kazmi, M. A., Ganim, Z., Hou, J. M., Pan, D., Chang, B. S., Sakmar, T. P., and Mathies, R. A. (2003) Retinal counterion switch in the photoactivation of the G protein-coupled receptor rhodopsin. *Proc. Natl. Acad. Sci. U.S.A.* **100,** 9262–9267
- 49. Lüdeke, S., Beck, M., Yan, E. C., Sakmar, T. P., Siebert, F., and Vogel, R. (2005) The role of Glu-181 in the photoactivation of rhodopsin. *J. Mol. Biol.* **353,** 345–356
- 50. Davidson, F. F., Loewen, P. C., and Khorana, H. G. (1994) Structure and function in rhodopsin: replacement by alanine of cysteine residues 110 and 187, components of a conserved disulfide bond in rhodopsin, affects the light-activated metarhodopsin II state. *Proc. Natl. Acad. Sci. U.S.A.* **91,** 4029–4033
- 51. Janz, J. M., and Farrens, D. L. (2003) Assessing structural elements that influence Schiff base stability: mutants E113Q and D190N destabilize rhodopsin through different mechanisms. *Vision Res.* **43,** 2991–3002
- 52. Janz, J. M., Fay, J. F., and Farrens, D. L. (2003) Stability of dark state rhodopsin is mediated by a conserved ion pair in intradiscal loop E-2. *J. Biol. Chem.* **278,** 16982–16991
- 53. Angel, T. E., Chance, M. R., and Palczewski, K. (2009) Conserved waters mediate structural and functional activation of family A (rhodopsinlike) G protein-coupled receptors. *Proc. Natl. Acad. Sci. U.S.A.* **106,** 8555–8560
- 54. Yan, E. C., Epps, J., Lewis, J. W., Szundi, I., Bhagat, A., Sakmar, T. P., and Kliger, D. S. (2007) *J. Phys. Chem. C* **111,** 8843–8848
- 55. Yan, E. C., Ganim, Z., Kazmi, M. A., Chang, B. S., Sakmar, T. P., and Mathies, R. A. (2004) Resonance Raman analysis of the mechanism of energy storage and chromophore distortion in the primary visual photoproduct. *Biochemistry* **43,** 10867–10876
- 56. Sandberg, M. N., Amora, T. L., Ramos, L. S., Chen, M. H., Knox, B. E., and Birge, R. R. (2011) Glutamic acid 181 is negatively charged in the bathorhodopsin photointermediate of visual rhodopsin. *J. Am. Chem. Soc.* **133,** 2808–2811
- 57. Hwa, J., Reeves, P. J., Klein-Seetharaman, J., Davidson, F., and Khorana, H. G. (1999) Structure and function in rhodopsin: further elucidation of the role of the intradiscal cysteines, Cys-110, -185, and -187, in rhodopsin folding and function. *Proc. Natl. Acad. Sci. U.S.A.* **96,** 1932–1935
- 58. Krebs, M. P., Holden, D. C., Joshi, P., Clark, C. L., 3rd, Lee, A. H., and Kaushal, S. (2010) Molecular mechanisms of rhodopsin retinitis pigmentosa and the efficacy of pharmacological rescue. *J. Mol. Biol.* **395,** 1063–1078
- 59. Matias-Florentino, M., Ayala-Ramirez, R., Graue-Wiechers, F., and Zenteno, J. C. (2009) Molecular screening of rhodopsin and peripherin/ RDS genes in Mexican families with autosomal dominant retinitis pigmentosa. *Curr. Eye Res.* **34,** 1050–1056
- 60. Tsui, I., Chou, C. L., Palmer, N., Lin, C. S., and Tsang, S. H. (2008) Phenotype-genotype correlations in autosomal dominant retinitis pigmentosa caused by RHO, D190N. *Curr. Eye Res.* **33,** 1014–1022
- 61. Kaushal, S., and Khorana, H. G. (1994) Structure and function in rhodopsin. 7. Point mutations associated with autosomal dominant retinitis pigmentosa. *Biochemistry* **33,** 6121–6128
- 62. Molday, R. S., and MacKenzie, D. (1983) Monoclonal antibodies to rhodopsin: characterization, cross-reactivity, and application as structural probes. *Biochemistry* **22,** 653–660
- 63. Ferretti, L., Karnik, S. S., Khorana, H. G., Nassal, M., and Oprian, D. D. (1986) Total synthesis of a gene for bovine rhodopsin. *Proc. Natl. Acad. Sci. U.S.A.* **83,** 599–603
- 64. Reeves, P. J., Callewaert, N., Contreras, R., and Khorana, H. G. (2002) Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous *N*-glycosylation by a tetracycline-inducible *N*-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. *Proc. Natl. Acad. Sci. U.S.A.* **99,** 13419–13424
- 65. Reeves, P. J., Kim, J. M., and Khorana, H. G. (2002) Structure and function in rhodopsin: a tetracycline-inducible system in stable mammalian cell lines for high-level expression of opsin mutants. *Proc. Natl. Acad. Sci. U.S.A.* **99,** 13413–13418
- 66. Oprian, D. D., Molday, R. S., Kaufman, R. J., and Khorana, H. G. (1987) Expression of a synthetic bovine rhodopsin gene in monkey kidney cells. *Proc. Natl. Acad. Sci. U.S.A.* **84,** 8874–8878
- 67. Min, K. C., Zvyaga, T. A., Cypess, A. M., and Sakmar, T. P. (1993) Characterization of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. Mutations on the cytoplasmic surface affect transducin activation. *J. Biol. Chem.* **268,** 9400–9404
- 68. Sakmar, T. P., Franke, R. R., and Khorana, H. G. (1989) Glutamic acid 113 serves as the retinylidene Schiff base counterion in bovine rhodopsin. *Proc. Natl. Acad. Sci. U.S.A.* **86,** 8309–8313
- 69. Wald, G., and Brown, P. K. (1953) The molar extinction of rhodopsin. *J. Gen. Physiol.* **37,** 189–200
- 70. Kito, Y., Suzuki, T., Azuma, M., and Sekoguti, Y. (1968) Absorption spectrum of rhodopsin denatured with acid. *Nature* **218,** 955–957
- 71. Ozaki, K., Terakita, A., Hara, R., and Hara, T. (1986) Rhodopsin and retinochrome in the retina of a marine gastropod, *Conomulex luhuanus*. *Vi-*

sion Res. **26,** 691–705

- 72. Sancho-Pelluz, J., Tosi, J., Hsu, C.W., Lee, F.,Wolpert, K., Tabacaru, M. R., Greenberg, J. P., Tsang, S. H., and Lin, C. S. (2012) Mice with a D190N mutation in the gene encoding rhodopsin: a model for human autosomaldominant retinitis pigmentosa. *Mol. Med.* **18,** 549–555
- 73. Angel, T. E., Gupta, S., Jastrzebska, B., Palczewski, K., and Chance, M. R.

(2009) Structural waters define a functional channel mediating activation of the GPCR, rhodopsin. *Proc. Natl. Acad. Sci. U.S.A.* **106,** 14367–14372

74. Fishman, G. A., Vandenburgh, K., Stone, E. M., Gilbert, L. D., Alexander, K. R., and Sheffield, V. C. (1992) Ocular findings associated with rhodopsin gene codon 267 and codon 190 mutations in dominant retinitis pigmentosa. *Arch. Ophthalmol.* **110,** 1582–1588

